Immunic, Inc.
IMUX
$1.18
-$0.02-1.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.25M | 21.00M | 19.38M | 18.15M | 18.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.23M | 105.53M | 105.27M | 101.00M | 98.05M |
| Operating Income | -103.23M | -105.53M | -105.27M | -101.00M | -98.05M |
| Income Before Tax | -97.17M | -103.05M | -101.84M | -96.40M | -100.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -97.17 | -103.05 | -101.84 | -96.40 | -100.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.17M | -103.05M | -101.84M | -96.40M | -100.51M |
| EBIT | -103.23M | -105.53M | -105.27M | -101.00M | -98.05M |
| EBITDA | -103.06M | -105.37M | -105.10M | -100.85M | -97.92M |
| EPS Basic | -0.79 | -0.94 | -1.05 | -0.98 | -1.01 |
| Normalized Basic EPS | -0.47 | -0.57 | -0.64 | -0.60 | -0.60 |
| EPS Diluted | -0.79 | -0.94 | -1.05 | -0.98 | -1.01 |
| Normalized Diluted EPS | -0.47 | -0.57 | -0.64 | -0.60 | -0.60 |
| Average Basic Shares Outstanding | 577.02M | 483.40M | 390.78M | 393.40M | 400.55M |
| Average Diluted Shares Outstanding | 577.02M | 483.40M | 390.78M | 393.40M | 400.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |